- Three accepted abstracts will be presented virtually in a pre-recorded poster session
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that three abstracts have been accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held virtually from December 5-8, 2020. The presentations will focus on the company’s anti-BCMA allogeneic CAR T candidate, CYAD-211, and autologous NKG2D receptor-based CAR T candidates CYAD-01 and CYAD-02. In addition, the abstracts will be published online in the November supplemental issue of peer-reviewed journal Blood.
ASH 2020 Presentation Details:
The following abstracts published today are now available on the ASH conference website. Following their presentation at the meeting, the posters will be available in the Scientific Publications section of Celyad Oncology’s website.
Publication #1428: Clinical Development of a Non-Gene-Edited Allogeneic BCMA-Targeting CAR T-cell Product in Relapsed or Refractory Multiple Myeloma
Session Name: 703. Adoptive Immunotherapy: Poster I
Date: Saturday, December 5, 2020 from 7:00 a.m. to 3:30 p.m. PT
Publication #993: Results from the Phase I Clinical Studies Evaluating CYAD-01, a first-generation NKG2D CAR T-cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
Session Name: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I
Date: Saturday, December 5, 2020 from 7:00 a.m. to 3:30 p.m. PT
Publication #990: First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating CYAD-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
Session Name: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I
Date: Saturday, December 5, 2020 from 7:00 a.m. to 3:30 p.m. PT
About CYAD-211
CYAD-211 is an investigational, short hairpin RNA (shRNA)-based allogeneic CAR T candidate for the treatment of relapsed or refractory multiple myeloma (r/r MM). CYAD-211 is engineered to co-express a BCMA targeting chimeric antigen receptor and a single shRNA, which interferes with the expression of the CD3ζ component of the T cell receptor (TCR) complex. In July 2020, Celyad Oncology announced FDA Clearance of its IND application for CYAD-211.
About CYAD-01
CYAD-01 is an investigational CAR T therapy in which a patient’s T cells are engineered to express a chimeric antigen receptor (CAR) based on NKG2D, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands expressed on tumor cells.
About CYAD-02
CYAD-02 is an
investigational CAR T therapy that engineers an all-in-one vector approach in
patient’s T cells to express both (i) the NKG2D chimeric antigen receptor
(CAR), a receptor expressed on natural killer cells that binds to eight
stress-induced ligands expressed on tumor cells, and (ii) short hairpin RNA
(shRNA) SMARTvector technology licensed from Horizon Discovery to knockdown the
expression of NKG2D ligands MICA and MICB on the CAR T cells. In preclinical
models, shRNA-mediated knockdown of MICA and MICB expression on NKG2D CAR T
cells has shown enhanced in vitro expansion, as well as enhanced in vivo
engraftment and persistence, of the CAR T cells, as compared to
first-generation NKG2D receptor based CAR T cells.
